Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 6/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20283141 | 0.85 | CHRM2 (0.39) | CHRM2HRH4CHRM5CHRM1CHRM3 | |
| SCHEMBL24967959 | 0.76 | SMN1; SMN2 (0.46) | HRH4SLC6A9 | |
| SCHEMBL31381284 | 0.75 | KDM4E (0.50) | LCATCHRM2SLC6A9 | |
| SCHEMBL8693976 | 0.75 | KDM4E (0.58) | HRH4 | |
| SCHEMBL31381330 | 0.74 | LMNA (0.66) | LCATCHRM2SLC6A9 | |
| SCHEMBL18231725 | 0.73 | CHRM2 (0.43) | LCATCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL3919810 | 0.73 | ADRB1 (0.50) | LCAT | |
| SCHEMBL12683436 | 0.73 | CHRM2 (0.43) | LCATCHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL5211979 | 0.73 | HRH3 (0.48) | TIPARPSLC6A9 | |
| SCHEMBL23296939 | 0.73 | OGA (0.41) | LCATCHRM2PTPN11HRH4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | LCAT 4368/4885CHRM2 4846/4885PTPN11 4271/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | LCAT 4600/4885CHRM2 4745/4885PTPN11 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.